Lataa...
Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
BACKGROUND: Several disease-modifying drugs have shown promising effects on cognitive impairment in multiple sclerosis (MS). Alemtuzumab, a humanized monoclonal antibody, is effective in controlling disease activity, however, has not been evaluated for its effects on cognition in detail so far. OBJE...
Tallennettuna:
| Julkaisussa: | Front Neurol |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5775967/ https://ncbi.nlm.nih.gov/pubmed/29387035 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2017.00730 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|